November 30, 2025Cancer ScienceOpen Access

Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma

View Full Paper

Ask AI

Bookmark

Elevated kynurenine levels indicate poor prognosis in relapsed multiple myeloma patients, emphasizing IDO's role.
Two multiple myeloma cell lines significantly upregulated IDO and PD-L1 in stromal cells through cytokine signaling pathways.
Analysis of gene expression revealed critical pathways involving IRF1 and Janus kinase inhibition in stromal response.
Findings support targeting the JAK–STAT1–NF‐κB–IRF1 pathway to enhance immunotherapy in multiple myeloma.

Discussion

No takes yet. Share an insight, caveat, or question.

Analysis shows Janus kinase inhibition reduces IDO upregulation in stromal cells, suggesting improved outcomes in multiple myeloma immunotherapy.

Ebina et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis shows Janus kinase inhibition reduces IDO upregulation in stromal cells, suggesting improved outcomes in multiple myeloma immunotherapy.